Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04598009 · ClinicalTrials.gov registry record · Phase 2
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
A Phase 2 study of Melanoma Stage IV and Melanoma Stage III, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 2
- Study locations
NCT04598009 is a Phase 2 study of Melanoma Stage IV and Melanoma Stage III that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 25 participants, below the 101-participant average among 17 other Melanoma Stage IV trials with a reported enrollment target (75% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT04598009, a Phase 2 study of Melanoma Stage IV and Melanoma Stage III, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial studies how well binimetinib and imatinib work in treating patients with stage III-IV KIT-mutant melanoma that cannot be removed by surgery (unresectable). Binimetinib and imatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving binimetinib and imatinib may help treat patients with KIT-mutant melanoma.
Conditions Studied
Interventions
- DRUG Binimetinib
- DRUG Imatinib
Study Locations (2)
California
- UC San Diego Moores Cancer Center - La Jolla
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-03-03 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04598009
The ClinicalTrials.gov registry entry for NCT04598009 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 101-participant average among 17 other Melanoma Stage IV trials with a reported enrollment target (75% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Melanoma Stage IV appearing as the primary indexed condition, and to 2 interventions - of which Binimetinib is the first listed.
NCT04598009 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04598009 about?
NCT04598009 is a clinical study titled "Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma". This phase II trial studies how well binimetinib and imatinib work in treating patients with stage III-IV KIT-mutant melanoma that cannot be removed by surgery (unresectable). Binimetinib and imatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving b...
What is the current status of trial NCT04598009?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2021-03-03. Estimated completion is 2027-05-31.
What conditions does trial NCT04598009 study?
This clinical trial studies the following conditions: Melanoma Stage IV, Melanoma Stage III.
What interventions are being tested in trial NCT04598009?
The interventions under investigation include: Binimetinib (DRUG), Imatinib (DRUG).
Who is sponsoring clinical trial NCT04598009?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04598009 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma Stage IV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
-
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
RECRUITING · Phase 2
-
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients
RECRUITING · Phase 2
-
Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.